Trial Profile
A Phase II Trial of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Nov 2023
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms SIIS
- 21 Nov 2023 Status changed from recruiting to completed.
- 08 Dec 2011 New trial record